Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT ID: NCT07145255
Last Updated: 2026-01-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
150 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-03
Study Completion Date
2029-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141
Specific Advanced Solid Tumors
RECRUITING
PHASE1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066
Gastric Adenocarcinoma
Advanced Pancreatic Ductal Adenocarcinoma
Esophageal Adenocarcinoma
+2 more
RECRUITING
PHASE1
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
NCT04244552
Breast Cancer
Colorectal Cancer
Ovarian Cancer
+13 more
TERMINATED
PHASE1
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
NCT03811652
Non Small Cell Lung Cancer Squamous (NSCLC-Sq)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Small Cell Lung Cancer (SCLC)
+3 more
COMPLETED
PHASE1
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952
Solid Tumors
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Phase 1a will characterize safety and identify potential optimal biologically relevant doses (OBRDs), Recommended Phase 2 Doses (RP2Ds), and the maximum tolerated dose (MTD) of MBRC-201 at one or more dosing regimens.
Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-201 at the potential OBRDs, RP2Ds, and dosing regimens identified in Phase 1a. The initial Phase 2 portion will begin when the RP2D has been determined from Phase 1a and Phase1b data. Phase 1b will enroll at least 4 expansion cohorts of approximately 20 patients per cohort (n ≈ 80 total) with the following tumor types: patients with mCRPC with confirmed adenocarcinoma histology, patients with advanced metastatic NSCLC refractory to standard treatment, patients with advanced metastatic breast cancer (TNBC, HR+/HER2-low or -negative, or HR-/HER2-low) refractory to standard treatment, and patients with advanced metastatic CRC or PDAC refractory to standard treatment.
The initial Phase 2 will enroll approximately 30 patients to further evaluate antitumor activity and safety of MBRC-201 at the RP2D determined during Phase 1b. Phase 2 will enroll patients in tumor-specific cohorts from the indications evaluated in Phase 1a/1b.
Phase 1a, Phase 1b and Phase 2 will characterize single and multiple-dose PK profiles and evaluate incidence and persistence of anti-MBRC-201 antibody (Ab) \[ADA\] formation. Safety will be assessed at each dose escalation in Phase 1a and ad hoc throughout Phase 1b and Phase 2.
A Safety Review Committee (SRC), consisting of the site investigators and representatives from the Sponsor will monitor patient safety and make dosing recommendations throughout the study.
The duration of the study (e.g., from the first patient enrolled through completion of LTFU data collection) is estimated to be approximately 48 months. There will also be long-term follow-up (LTFU) for safety, disease status, and survival assessments, which will continue until death or lost to follow-up, withdrawal of consent for further follow-up, or study termination whichever occurs first
Phase 1a will characterize safety and identify potential optimal biologically relevant doses (OBRDs), Recommended Phase 2 Doses (RP2Ds), and the maximum tolerated dose (MTD) of MBRC-201 at one or more dosing regimens.
Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-201 at the potential OBRDs, RP2Ds, and dosing regimens identified in Phase 1a. The initial Phase 2 portion will begin when the RP2D has been determined from Phase 1a and Phase1b data. Phase 1b will enroll at least 4 expansion cohorts of approximately 20 patients per cohort (n ≈ 80 total) with the following tumor types: patients with mCRPC with confirmed adenocarcinoma histology, patients with advanced metastatic NSCLC refractory to standard treatment, patients with advanced metastatic breast cancer (TNBC, HR+/HER2-low or -negative, or HR-/HER2-low) refractory to standard treatment, and patients with advanced metastatic CRC or PDAC refractory to standard treatment.
The initial Phase 2 will enroll approximately 30 patients to further evaluate antitumor activity and safety of MBRC-201 at the RP2D determined during Phase 1b. Phase 2 will enroll patients in tumor-specific cohorts from the indications evaluated in Phase 1a/1b.
Phase 1a, Phase 1b and Phase 2 will characterize single and multiple-dose PK profiles and evaluate incidence and persistence of anti-MBRC-201 antibody (Ab) \[ADA\] formation. Safety will be assessed at each dose escalation in Phase 1a and ad hoc throughout Phase 1b and Phase 2.
A Safety Review Committee (SRC), consisting of the site investigators and representatives from the Sponsor will monitor patient safety and make dosing recommendations throughout the study.
The duration of the study (e.g., from the first patient enrolled through completion of LTFU data collection) is estimated to be approximately 48 months. There will also be long-term follow-up (LTFU) for safety, disease status, and survival assessments, which will continue until death or lost to follow-up, withdrawal of consent for further follow-up, or study termination whichever occurs first
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Prostate Cancer Castration-resistant Prostate Cancer
Breast Cancer
Colo-rectal Cancer
Lung Cancer (Non-Small Cell)
Pancreas Cancer, Duct Cell Adenocarcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1a
Dose Escalation
Group Type
EXPERIMENTAL
ADC
Intervention Type
DRUG
MBRC-201 ADC
Phase 1b
Dose Expansion
Group Type
EXPERIMENTAL
ADC
Intervention Type
DRUG
MBRC-201 ADC
Phase 2
Recommended Phase 2 Dose
Group Type
EXPERIMENTAL
ADC
Intervention Type
DRUG
MBRC-201 ADC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADC
MBRC-201 ADC
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific evaluation. Patients should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures.
2. 18 years of age or older at the time of informed consent.
3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions:
* Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.
* Must agree not to try to become pregnant during the study and for at least 6 months after the final dose of MBRC-201
* Must agree to practice effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) and willing to continue to use effective contraception for the duration of study participation and for 6 months after the final dose of study drug.
4. Male patients whose partners are of childbearing potential must agree to use effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) (Section 10.4) for the duration of study participation and for 6 months after the final dose of study drug.
5. Have a histologic or cytologic diagnosis of malignant solid tumor for which there are no standard-of-care treatment options known to confer a clinical benefit or for which the patient is ineligible or declines (except for Phase 1b-Cohort A).
A. For Phase 1a dose escalation: Patients must have one of the following tumor types:
i. mCRPC, breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+), CRC, NSCLC, or PDAC
B. For Phase 1b: Patients must have one of the following tumor types:
i. Cohort A: Histologic or cytologic diagnosis of mCRPC (with confirmed adenocarcinoma histology) refractory to standard treatment.
Patients must have had prior exposure to at least one novel AR-targeted therapy (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide). Prior taxane or lutetium Lu 177 vipivotide tetraxetan is acceptable but not required.
ii. Cohort B: Histologic or cytologic diagnosis of advanced metastatic NSCLC refractory to standard treatment.
iii. Cohort C: Histologic or cytologic diagnosis of advanced metastatic breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+) refractory to standard treatment.
iv. Cohort D: Histologic or cytologic diagnosis of advanced metastatic CRC, PDAC refractory to standard treatment. The Sponsor may add or remove specific tumor indications based on emerging, real-time study results.
6. Availability of a tumor tissue sample (formalin-fixed paraffin-embedded \[FFPE\]) must be confirmed if feasible. Patients without tumor sample may be eligible with medical monitor approval. Tumor biopsies are not required and should not be performed to assess eligibility.
7. For Dose Escalation (Phase 1a), patients may have evaluable disease or measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. For both Dose Expansion (Phase 1b) and Phase 2, patients must have measurable disease according to RECIST v1.1
8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
9. Life expectancy ≥ 3 months
10. Patient must have adequate organ and marrow function as defined below.
* Absolute neutrophil count (ANC) ≥ 1500/uL
* Hemoglobin (Hgb) ≥ 9 g/dL
* Platelet count ≥ 100,000/uL
* International normalized ratio (INR) \< 1.5 (or ≤ 3.0 if on therapeutic anticoagulation)
* Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min by the CKD-EPI or similar equation or as measured by 24-hour urine collection
* Total bilirubin ≤ 1.5 × ULN \[or ≤ 3-times ULN for patients with Gilbert's disease or documented hepatic tumor involvement\]
* ALT and AST ≤ 3 × ULN \[or ≤ 5-times ULN for patients with documented hepatic tumor involvement\]
2. 18 years of age or older at the time of informed consent.
3. Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing; must be documented) or patients of childbearing potential under the following conditions:
* Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.
* Must agree not to try to become pregnant during the study and for at least 6 months after the final dose of MBRC-201
* Must agree to practice effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) and willing to continue to use effective contraception for the duration of study participation and for 6 months after the final dose of study drug.
4. Male patients whose partners are of childbearing potential must agree to use effective contraception (must agree to use 2 forms of contraception, 1 of which must be a barrier method) (Section 10.4) for the duration of study participation and for 6 months after the final dose of study drug.
5. Have a histologic or cytologic diagnosis of malignant solid tumor for which there are no standard-of-care treatment options known to confer a clinical benefit or for which the patient is ineligible or declines (except for Phase 1b-Cohort A).
A. For Phase 1a dose escalation: Patients must have one of the following tumor types:
i. mCRPC, breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+), CRC, NSCLC, or PDAC
B. For Phase 1b: Patients must have one of the following tumor types:
i. Cohort A: Histologic or cytologic diagnosis of mCRPC (with confirmed adenocarcinoma histology) refractory to standard treatment.
Patients must have had prior exposure to at least one novel AR-targeted therapy (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide). Prior taxane or lutetium Lu 177 vipivotide tetraxetan is acceptable but not required.
ii. Cohort B: Histologic or cytologic diagnosis of advanced metastatic NSCLC refractory to standard treatment.
iii. Cohort C: Histologic or cytologic diagnosis of advanced metastatic breast cancer (TNBC, HR+/HER2-negative or HER2-low, HR-/HER2+) refractory to standard treatment.
iv. Cohort D: Histologic or cytologic diagnosis of advanced metastatic CRC, PDAC refractory to standard treatment. The Sponsor may add or remove specific tumor indications based on emerging, real-time study results.
6. Availability of a tumor tissue sample (formalin-fixed paraffin-embedded \[FFPE\]) must be confirmed if feasible. Patients without tumor sample may be eligible with medical monitor approval. Tumor biopsies are not required and should not be performed to assess eligibility.
7. For Dose Escalation (Phase 1a), patients may have evaluable disease or measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. For both Dose Expansion (Phase 1b) and Phase 2, patients must have measurable disease according to RECIST v1.1
8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
9. Life expectancy ≥ 3 months
10. Patient must have adequate organ and marrow function as defined below.
* Absolute neutrophil count (ANC) ≥ 1500/uL
* Hemoglobin (Hgb) ≥ 9 g/dL
* Platelet count ≥ 100,000/uL
* International normalized ratio (INR) \< 1.5 (or ≤ 3.0 if on therapeutic anticoagulation)
* Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min by the CKD-EPI or similar equation or as measured by 24-hour urine collection
* Total bilirubin ≤ 1.5 × ULN \[or ≤ 3-times ULN for patients with Gilbert's disease or documented hepatic tumor involvement\]
* ALT and AST ≤ 3 × ULN \[or ≤ 5-times ULN for patients with documented hepatic tumor involvement\]
Exclusion Criteria
1. History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Allowed exceptions are patients with:
1. Non-melanoma skin cancer considered completely cured;
2. Localized prostate cancer treated with curative intent with no evidence of progression;
3. Low-risk or very low-risk (per standard clinical guidelines) localized prostate cancer under active surveillance without immediate intent to treat;
4. Malignancy that is otherwise considered cured with minimal risk of recurrence.
2. Known or suspected sensitivity to any of the ingredients of the investigational product MBRC-201.
3. Active cerebral/meningeal disease related to the underlying malignancy. Patients with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the patient is clinically stable. (defined as not having received steroid treatment for symptoms related to cerebral/meningeal disease for at least 2 weeks prior to the first dose of study drug and with no ongoing related AEs).
4. Any uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug, unless deemed not clinically significant by the investigator (e.g., onychomycosis). Routine antimicrobial prophylaxis is permitted.
5. Active or symptomatic viral hepatitis, including patients with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients who have been treated for hepatitis C infection or who have spontaneously recovered are permitted.
6. Patients with HIV infection with 1 or more of the following:
* Acquired immunodeficiency syndrome (AIDs)-defining opportunistic infection within 6 months of the start of screening
* A change in antiretroviral therapy within 3 months of the start of screening and viral load \> 500 copies/mL
* Receiving antiretroviral therapy that may interfere with study drug
* CD4 count \< 350 at screening
7. Thromboembolic events and/or bleeding disorders ≤ 14 days (e.g., venous thromboembolism \[VTE\] or pulmonary embolism \[or PE\]) prior to the first dose of study drug
8. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug
9. A baseline QT (time from the beginning of the Q wave to the end of the T wave) interval as corrected by Fridericia's formula (QTcF) \> 470 msec or patients with risk factors for Torsades de pointes
10. Uncontrolled Inflammatory Bowel Disease (IBD)
11. A history of (non-infectious) ILD/pneumonitis requiring steroid therapy, or active ILD/pneumonitis, or clinically suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
12. Uncontrolled autoimmune disease or syndrome
13. Active ocular surface disease at screening, including confluent superficial keratitis, cornea epithelial defect, corneal ulcer or stromal opacity or any components of the ophthalmologic history which, in the investigator's opinion, may place the patient at significant risk. Cataracts alone are not an exclusion criterion.
14. Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer (anti-hormonal therapy given for advanced prostate cancer or as adjuvant therapy for early stage, HR positive breast cancer is not considered cancer therapy for the purpose of this protocol).
15. Use of any investigational drug within 14 days prior to the first dose of study drug.
16. For Phase 1b and Phase 2: prior treatment with an ADC with a camptothecin (CPT) payload, such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan), or Trodelvy (sacituzumab govitecan). Prior treatment with irinotecan and other non-ADC topoisomerase inhibitors is allowed in all phases of the study.
17. Current use of any prohibited concomitant medication(s).
18. Major surgery within 28 days prior to first dose of study drug.
19. Patients who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia
20. Any medical, psychiatric, addictive, or other kind of disorder which compromises the ability of the patient to give written informed consent and/or to comply with procedures.
21. Condition or situation which, based on Investigator or Sponsor assessment, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study.
22. Other serious underlying medical condition that would impair the patient's ability to receive or tolerate the planned treatment and follow-up
1. Non-melanoma skin cancer considered completely cured;
2. Localized prostate cancer treated with curative intent with no evidence of progression;
3. Low-risk or very low-risk (per standard clinical guidelines) localized prostate cancer under active surveillance without immediate intent to treat;
4. Malignancy that is otherwise considered cured with minimal risk of recurrence.
2. Known or suspected sensitivity to any of the ingredients of the investigational product MBRC-201.
3. Active cerebral/meningeal disease related to the underlying malignancy. Patients with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the patient is clinically stable. (defined as not having received steroid treatment for symptoms related to cerebral/meningeal disease for at least 2 weeks prior to the first dose of study drug and with no ongoing related AEs).
4. Any uncontrolled viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug, unless deemed not clinically significant by the investigator (e.g., onychomycosis). Routine antimicrobial prophylaxis is permitted.
5. Active or symptomatic viral hepatitis, including patients with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months). Patients who have been treated for hepatitis C infection or who have spontaneously recovered are permitted.
6. Patients with HIV infection with 1 or more of the following:
* Acquired immunodeficiency syndrome (AIDs)-defining opportunistic infection within 6 months of the start of screening
* A change in antiretroviral therapy within 3 months of the start of screening and viral load \> 500 copies/mL
* Receiving antiretroviral therapy that may interfere with study drug
* CD4 count \< 350 at screening
7. Thromboembolic events and/or bleeding disorders ≤ 14 days (e.g., venous thromboembolism \[VTE\] or pulmonary embolism \[or PE\]) prior to the first dose of study drug
8. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug
9. A baseline QT (time from the beginning of the Q wave to the end of the T wave) interval as corrected by Fridericia's formula (QTcF) \> 470 msec or patients with risk factors for Torsades de pointes
10. Uncontrolled Inflammatory Bowel Disease (IBD)
11. A history of (non-infectious) ILD/pneumonitis requiring steroid therapy, or active ILD/pneumonitis, or clinically suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
12. Uncontrolled autoimmune disease or syndrome
13. Active ocular surface disease at screening, including confluent superficial keratitis, cornea epithelial defect, corneal ulcer or stromal opacity or any components of the ophthalmologic history which, in the investigator's opinion, may place the patient at significant risk. Cataracts alone are not an exclusion criterion.
14. Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer (anti-hormonal therapy given for advanced prostate cancer or as adjuvant therapy for early stage, HR positive breast cancer is not considered cancer therapy for the purpose of this protocol).
15. Use of any investigational drug within 14 days prior to the first dose of study drug.
16. For Phase 1b and Phase 2: prior treatment with an ADC with a camptothecin (CPT) payload, such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan), or Trodelvy (sacituzumab govitecan). Prior treatment with irinotecan and other non-ADC topoisomerase inhibitors is allowed in all phases of the study.
17. Current use of any prohibited concomitant medication(s).
18. Major surgery within 28 days prior to first dose of study drug.
19. Patients who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia
20. Any medical, psychiatric, addictive, or other kind of disorder which compromises the ability of the patient to give written informed consent and/or to comply with procedures.
21. Condition or situation which, based on Investigator or Sponsor assessment, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study.
22. Other serious underlying medical condition that would impair the patient's ability to receive or tolerate the planned treatment and follow-up
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MBrace Therapeutics
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
START, Midwest
Grand Rapids, Michigan, United States
Site Status
RECRUITING
START, Astera
East Brunswick, New Jersey, United States
Site Status
RECRUITING
NEXT, Dallas
Irving, Texas, United States
Site Status
RECRUITING
START San Antonio
San Antonio, Texas, United States
Site Status
RECRUITING
START, Mountain Region
West Valley City, Utah, United States
Site Status
RECRUITING
NEXT, Virginia
Fairfax, Virginia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abigail VanKirk
Role: backup
616-389-1810
Mofopefoluwa Akinwale
Role: backup
Maybelle De La Rosa
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBRC-201-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
NCT03762447
COMPLETED
PHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
RECRUITING
PHASE1
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
NCT05652855
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706
RECRUITING
PHASE1
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
NCT04903873
RECRUITING
PHASE1/PHASE2
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488
COMPLETED
PHASE1
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107
RECRUITING
PHASE1/PHASE2
A Study of ABT-165 in Subjects With Solid Tumors
NCT01946074
COMPLETED
PHASE1
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
NCT02179918
COMPLETED
PHASE1
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
NCT00582985
COMPLETED
PHASE1
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
NCT06548672
RECRUITING
PHASE1
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
NCT07126665
RECRUITING
PHASE1/PHASE2
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247
RECRUITING
PHASE1/PHASE2
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
NCT07223125
RECRUITING
PHASE1
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005
RECRUITING
PHASE1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06752681
RECRUITING
PHASE1
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155
ACTIVE_NOT_RECRUITING
PHASE1
Safety Study of AMG 228 to Treat Solid Tumors
NCT02437916
TERMINATED
PHASE1
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662
TERMINATED
PHASE1
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760525
COMPLETED
PHASE1
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
NCT05858736
ACTIVE_NOT_RECRUITING
PHASE1
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
RECRUITING
PHASE1
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
NCT05514444
COMPLETED
PHASE1
A Study of MHB048C in Patients With Advanced Solid Tumors
NCT07192120
RECRUITING
PHASE1/PHASE2
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2